Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.55
Percentage change 3.34	%

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI VB IWM VXF VBK IWO AVUV CGGR IBB VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	11.19%	Shs Outstand	111.48M	Perf Week	-11.04%
Market Cap	1.90B	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-0.67%	Shs Float	99.01M	Perf Month	2.10%
Income	-164.19M	PEG	-	EPS next Q	-0.38	Inst Own	85.15%	Short Float	5.45%	Perf Quarter	-15.76%
Sales	621.71M	P/S	3.05	EPS this Y	-4.67%	Inst Trans	4.13%	Short Ratio	5.54	Perf Half Y	-44.28%
Book/sh	3.25	P/B	5.24	EPS next Y	-6.91%	ROA	-13.85%	Short Interest	5.40M	Perf Year	-25.50%
Cash/sh	8.35	P/C	2.04	EPS next 5Y	8.60%	ROE	-45.52%	52W Range	14.17 - 34.13	Perf YTD	-42.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-83.87%	ROI	-32.86%	52W High	-50.19%	Beta	0.75
Dividend TTM	-	Quick Ratio	1.41	Sales past 5Y	11.49%	Gross Margin	77.31%	52W Low	19.97%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	16.28%	Oper. Margin	-26.69%	RSI (14)	43.78	Volatility	2.38% 3.81%
Employees	1488	Debt/Eq	1.92	Sales Y/Y TTM	18.27%	Profit Margin	-26.41%	Recom	1.57	Target Price	32.57
Option/Short	Yes / Yes	LT Debt/Eq	0.38	EPS Q/Q	13.87%	Payout	-	Rel Volume	2.92	Prev Close	16.45
Sales Surprise	5.48%	EPS Surprise	33.20%	Sales Q/Q	11.91%	Earnings	Apr 24 BMO	Avg Volume	974.73K	Price	17.00
SMA20	-5.17%	SMA50	-2.85%	SMA200	-15.87%	Trades		Volume	2,844,992	Change	3.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82

Show Previous Ratings

Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
07:00AM	Loading…
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	Loading…
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)
07:00AM	FDA Approves Novocures Innovative HFE Transducer Arrays for Use With Optune Gio for Glioblastoma (Business Wire)
Oct-31-24 07:30AM	NovoCures Strong Q3 and Leadership Changes in 2024 (TipRanks) -10.65%
03:04AM	NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com)
Oct-30-24 11:00PM	NovoCure (NVCR) Q3 2024 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:02AM	Novocure Appoints Christoph Brackmann as Chief Financial Officer (Business Wire)
07:00AM	Novocure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-17-24 10:52AM	Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment (GuruFocus.com) -5.43%
08:00AM	NovoCure scoops FDA approval on wearable for metastatic cancer treatment (Clinical Trials Arena)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
08:16AM	Novocure wins FDA approval for electric field device in lung cancer (BioPharma Dive)
07:28AM	FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients (Benzinga)
06:26AM	Novocure shares soar 33% as FDA approves lung cancer treatment (Investing.com)
03:45AM	NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily) +10.71%
04:43PM	FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Oct-01-24 07:00AM	Novocure to Report Third Quarter 2024 Financial Results (Business Wire)
Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)
Sep-06-24 05:19PM	Why NovoCure Stock Dived by 13% This Week (Motley Fool) -6.48%
Sep-03-24 07:00AM	Novocure Announces Planned CEO Transition (Business Wire) -13.84%
Aug-28-24 07:00AM	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Business Wire) +9.61%
Aug-16-24 09:55AM	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet (Zacks) -5.34%
Aug-14-24 07:00AM	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Business Wire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
Jul-30-24 09:55AM	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade (Zacks) +12.24%
Jul-25-24 05:30PM	NovoCure (NVCR) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:11AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire) +7.17%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jul-01-24 07:00AM	Novocure to Report Second Quarter 2024 Financial Results (Business Wire)
Jun-14-24 10:44AM	Cramer's Lightning Round: Novocure, PayPal, AeroVironment (CNBC TV)
Jun-03-24 08:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Business Wire) +8.54%
May-23-24 05:05PM	TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany (Business Wire) -5.86%
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace) +13.01%
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.17%
May-03-24 12:08PM	NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:00AM	NovoCure (NVCR) Q1 2024 Earnings Call Transcript (Motley Fool)
May-02-24 01:19PM	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue (MT Newswires) +11.38%
11:56AM	NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:45AM	NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported (GuruFocus.com)
08:25AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:28AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Business Wire)
07:00AM	Novocure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM
Paravasthu Mukund	Chief Operating Officer	Jan 11 '25	Sale	26.81	2,160	57,906	31,437	Jan 15 04:23 PM
MUKUND PARAVASTHU	Officer	Jan 13 '25	Proposed Sale	26.75	2,160	57,788		Jan 13 05:28 PM
WILHELMUS C. GROENHUYSEN	Officer	Jan 02 '25	Proposed Sale	29.80	266,085	7,929,333		Jan 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	Nov 02 '24	Sale	16.69	44	734	3,459	Nov 06 04:27 PM
Puri Michal Nath	Chief Human Resources Officer	Oct 31 '24	Sale	15.79	810	12,792	110,093	Nov 04 04:34 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Nov 01 '24	Sale	15.94	598	9,531	161,236	Nov 04 04:34 PM
Paravasthu Mukund	Chief Operating Officer	Nov 01 '24	Sale	15.88	160	2,540	3,503	Nov 04 04:32 PM
Cordova Ashley	Chief Financial Officer	Aug 02 '24	Sale	20.14	688	13,857	219,179	Aug 05 04:25 PM

Open in Screener

SIBN

SI-BONE Inc

Jun 06 • 04:00PM ET

18.90

Dollar change -0.16
Percentage change -0.84	%

Healthcare • Medical Devices • USA • NASD

Peers: GMED ATEC OFIX MDT SYK ZBH JNJ IART BAX BVS

| Held by: IWM VTI VXF IWO IHI SCHA VTWO VHT IWC XHE

Index	RUT	P/E	-	EPS (ttm)	-0.64	Insider Own	13.30%	Shs Outstand	42.48M	Perf Week	0.00%
Market Cap	805.41M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-3.50%	Shs Float	36.95M	Perf Month	8.19%
Income	-26.55M	PEG	-	EPS next Q	-0.18	Inst Own	87.36%	Short Float	4.38%	Perf Quarter	17.68%
Sales	176.60M	P/S	4.56	EPS this Y	15.56%	Inst Trans	1.80%	Short Ratio	3.70	Perf Half Y	45.16%
Book/sh	3.94	P/B	4.80	EPS next Y	30.00%	ROA	-11.77%	Short Interest	1.62M	Perf Year	37.45%
Cash/sh	3.39	P/C	5.58	EPS next 5Y	21.46%	ROE	-15.96%	52W Range	11.70 - 20.05	Perf YTD	34.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.67%	ROI	-13.06%	52W High	-5.74%	Beta	0.95
Dividend TTM	-	Quick Ratio	7.26	Sales past 5Y	19.96%	Gross Margin	79.25%	52W Low	61.54%	ATR (14)	0.67
Dividend Ex-Date	-	Current Ratio	8.53	EPS Y/Y TTM	41.26%	Oper. Margin	-17.38%	RSI (14)	61.18	Volatility	2.22% 2.03%
Employees	349	Debt/Eq	0.22	Sales Y/Y TTM	22.60%	Profit Margin	-15.04%	Recom	1.00	Target Price	24.67
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	42.00%	Payout	-	Rel Volume	0.99	Prev Close	19.06
Sales Surprise	4.78%	EPS Surprise	33.54%	Sales Q/Q	24.88%	Earnings	May 05 AMC	Avg Volume	437.02K	Price	18.90
SMA20	0.12%	SMA50	17.83%	SMA200	24.55%	Trades		Volume	431,326	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-24	Reiterated	Needham	Buy	$27 → $19
Mar-28-24	Initiated	Piper Sandler	Overweight	$25
Oct-12-22	Initiated	Jefferies	Buy	$20
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$34
Jun-08-21	Initiated	Citigroup	Buy	$40
Mar-09-21	Reiterated	Needham	Buy	$35 → $34
Dec-16-20	Reiterated	Needham	Buy	$28 → $35
Aug-04-20	Reiterated	Needham	Buy	$22 → $24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$25
May-05-20	Reiterated	Needham	Buy	$27 → $22
Feb-19-20	Initiated	Needham	Buy	$27
Jan-08-20	Initiated	SunTrust	Buy	$27
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-12-18	Initiated	Morgan Stanley	Overweight	$24
Nov-12-18	Initiated	JMP Securities	Mkt Outperform	$27
Nov-12-18	Initiated	Canaccord Genuity	Buy	$25
Nov-12-18	Initiated	BofA/Merrill	Buy	$23

Show Previous Ratings

Jun-04-25 04:30PM	SI-BONE to Truist Securities MedTech Conference on June 17, 2025 (GlobeNewswire)
04:30PM	SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025 (GlobeNewswire)
May-28-25 04:30PM	SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025 (GlobeNewswire)
May-26-25 09:55AM	Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? (Zacks)
May-14-25 07:30AM	4 Recent Earnings Winners Riding Fresh Momentum in May (MarketBeat)
12:00PM	Loading…
May-13-25 12:00PM	What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-25 09:55AM	Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet (Zacks)
May-06-25 04:09PM	SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025 (GlobeNewswire) +15.44% +6.20%
08:35AM	Q1 2025 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	SI-BONE Inc (SIBN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Positive ... (GuruFocus.com)
May-05-25 05:20PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Si-Bone: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance (GlobeNewswire)
May-02-25 09:29AM	SI-BONE Inc (SIBN) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Apr-14-25 04:09PM	SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire)
10:42AM	Loading…
Apr-10-25 10:42AM	IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last? (Zacks)
Apr-08-25 07:00PM	SI-BONE, Inc.: Small-cap Developer Of Medical Implants And A Steady Revenue Grower (Seeking Alpha) +6.58%
Feb-26-25 10:01AM	SI-Bone price target raised to $24 from $20 at Needham (TipRanks)
Feb-25-25 09:03AM	Q4 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) +5.55%
02:03AM	SI-BONE Inc (SIBN) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Positive EBITDA (GuruFocus.com)
Feb-24-25 05:40PM	Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Si-Bone: Q4 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance (GlobeNewswire)
Feb-22-25 04:21PM	SI-BONE Inc (SIBN) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-21-25 08:00AM	Bruker Appoints Laura Francis to its Board of Directors (Business Wire)
Feb-17-25 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-03-25 04:09PM	SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 (GlobeNewswire) +5.29%
Jan-18-25 08:00AM	SI-Bone price target raised to $20 from $19 at Needham (TipRanks)
Jan-13-25 09:00AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024 (GlobeNewswire) +18.29%
Dec-12-24 09:55AM	Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade (Zacks)
09:55AM	Loading…
Nov-26-24 09:55AM	Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? (Zacks)
Nov-20-24 04:09PM	SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 (GlobeNewswire)
Nov-13-24 10:54AM	Q3 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
02:18AM	SI-BONE Inc (SIBN) Q3 2024 Earnings Call Highlights: Record Revenue and Path to Profitability (GuruFocus.com)
Nov-12-24 05:25PM	Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Si-Bone: Q3 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance (GlobeNewswire)
Nov-11-24 07:13AM	SI-BONE Inc (SIBN) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-05-24 08:30AM	SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite (GlobeNewswire) +6.75%
Oct-30-24 03:35AM	Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Oct-22-24 04:09PM	SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-14-24 07:28AM	First patients are treated with Si-Bones pelvic fracture fixation device (Medical Device Network)
Oct-10-24 08:30AM	SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation (GlobeNewswire)
Aug-26-24 09:55AM	Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
08:19AM	SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System (Zacks)
Aug-22-24 04:30PM	SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024 (GlobeNewswire) +11.07%
Aug-20-24 08:30AM	SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System (GlobeNewswire)
Aug-08-24 09:55AM	Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade (Zacks)
Aug-06-24 09:16AM	Q2 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024 (GlobeNewswire)
Aug-05-24 05:55PM	Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Si-Bone: Q2 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024 (GlobeNewswire)
Jul-15-24 04:09PM	SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024 (GlobeNewswire) +8.92%
Jun-05-24 04:09PM	SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024 (GlobeNewswire)
May-07-24 11:16AM	SI-BONE, Inc. (NASDAQ:SIBN) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.29%
09:00AM	SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures (GlobeNewswire)
08:04AM	Q1 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
03:08AM	SI-BONE Inc (SIBN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
May-06-24 05:25PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:24PM	Si-Bone: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the First Quarter 2024 (GlobeNewswire)
Apr-29-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
09:00AM	SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024 (GlobeNewswire)
Apr-15-24 04:09PM	SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire)
Mar-04-24 04:09PM	SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024 (GlobeNewswire)
Feb-27-24 06:49AM	Q4 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -13.53%
Feb-26-24 05:38PM	Si-Bone: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	SI-BONE Inc (SIBN) Reports Record Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:09PM	SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance (GlobeNewswire)
Feb-19-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:09PM	SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024 (GlobeNewswire)
Jan-30-24 08:30AM	SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:30AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023 (GlobeNewswire) -7.06%
Jan-05-24 09:02AM	SI-BONE Inc Director Davis Timothy E JR Sells 9,900 Shares (GuruFocus.com)
Nov-30-23 09:30AM	Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-21-23 07:03AM	Insider Sell: President, Commercial Ops Anthony Recupero Sells 8,457 Shares of SI-BONE Inc (SIBN) (GuruFocus.com)
Nov-14-23 04:09PM	SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 (GlobeNewswire) +9.47%
Nov-07-23 11:08AM	SI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:00AM	Q3 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:38PM	Si-Bone: Q3 Earnings Snapshot (Associated Press Finance)
05:01PM	SI-BONE Inc (SIBN) Reports Record Q3 2023 Financial Results, Raises Annual Guidance (GuruFocus.com)
04:09PM	SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance (GlobeNewswire)
Nov-01-23 04:09PM	SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023 (GlobeNewswire)
Oct-16-23 04:09PM	SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Oct-09-23 12:00PM	Si-Bone (SIBN) Upgraded to Buy: Here's Why (Zacks)
Sep-08-23 09:40AM	Has SiBone (SIBN) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-06-23 09:55AM	Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect? (Zacks)
Sep-05-23 04:09PM	SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods (GlobeNewswire)
Aug-29-23 04:09PM	SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023 (GlobeNewswire)
Aug-09-23 10:07AM	SI-BONE, Inc. (NASDAQ:SIBN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 06:23AM	Q2 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -11.17%
Aug-07-23 05:20PM	Si-Bone: Q2 Earnings Snapshot (AP Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance (GlobeNewswire)
Jul-19-23 04:09PM	SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023 (GlobeNewswire)
Jul-17-23 04:09PM	SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire)
Jul-06-23 10:00AM	Best Momentum Stocks to Buy for July 6th (Zacks)
May-29-23 10:15AM	Despite shrinking by US$86m in the past week, SI-BONE (NASDAQ:SIBN) shareholders are still up 69% over 1 year (Simply Wall St.)
May-24-23 04:09PM	SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023 (GlobeNewswire)

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUNN JEFFREY W	Director	Jun 05 '25	Sale	19.05	3,377	64,335	17,354	Jun 06 07:48 PM
FRANCIS LAURA	Chief Executive Officer	May 16 '25	Sale	19.67	12,385	243,670	495,170	May 20 07:48 PM
FRANCIS LAURA	Chief Executive Officer	May 19 '25	Sale	19.49	5,412	105,464	490,987	May 20 07:48 PM
Maheshwari Anshul	Chief Financial Officer	May 16 '25	Sale	19.76	9,585	189,399	224,507	May 20 07:47 PM
Maheshwari Anshul	Chief Financial Officer	May 19 '25	Sale	19.48	2,424	47,213	222,083	May 20 07:47 PM
RECUPERO ANTHONY J	President, Commercial Ops	May 16 '25	Sale	19.56	4,147	81,109	282,015	May 20 07:46 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	May 16 '25	Sale	19.66	3,459	68,006	264,636	May 20 07:45 PM
DAVID & LAURA FRANCIS JOINT RE	Director	May 19 '25	Proposed Sale	19.79	5,412	107,103		May 19 04:57 PM
ANSHUL MAHESHWARI	Officer	May 19 '25	Proposed Sale	19.79	2,424	47,971		May 19 04:57 PM
ANSHUL MAHESHWARI	Officer	May 16 '25	Proposed Sale	18.88	4,958	93,607		May 16 04:21 PM
Maheshwari Anshul	Chief Financial Officer	May 12 '25	Sale	19.02	4,937	93,926	232,069	May 14 08:33 PM
ANSHUL MAHESHWARI	Officer	May 12 '25	Proposed Sale	18.49	4,937	91,285		May 12 04:27 PM
FRANCIS LAURA	Chief Executive Officer	May 07 '25	Sale	17.18	38,504	661,368	302,958	May 09 07:01 PM
Maheshwari Anshul	Chief Financial Officer	May 08 '25	Sale	18.17	28,350	515,094	237,006	May 09 07:00 PM
Maheshwari Anshul	Chief Financial Officer	May 07 '25	Sale	17.00	4,937	83,939	265,356	May 09 07:00 PM
ANSHUL MAHESHWARI	Officer	May 08 '25	Proposed Sale	17.47	28,350	495,274		May 08 04:23 PM
ANSHUL MAHESHWARI	Officer	May 07 '25	Proposed Sale	16.45	4,937	81,214		May 07 04:21 PM
DAVID & LAURA FRANCIS JOINT RE	Officer	May 07 '25	Proposed Sale	16.45	38,504	633,391		May 07 04:21 PM
DUNN JEFFREY W	Director	May 01 '25	Sale	13.78	336	4,628	12,536	May 02 05:08 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	Apr 30 '25	Option Exercise	4.68	21,367	99,998	266,245	May 02 05:07 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	Apr 02 '25	Sale	14.14	3,128	44,219	244,878	Apr 04 05:14 PM
RECUPERO ANTHONY J	President, Commercial Ops	Apr 02 '25	Sale	14.15	3,311	46,853	284,555	Apr 04 05:13 PM
Maheshwari Anshul	Chief Financial Officer	Apr 02 '25	Sale	14.11	3,311	46,723	270,293	Apr 04 05:12 PM
FRANCIS LAURA	Chief Executive Officer	Feb 18 '25	Sale	17.22	46,233	795,915	506,761	Feb 21 04:19 PM
Maheshwari Anshul	Chief Financial Officer	Feb 18 '25	Sale	16.86	11,180	188,518	273,604	Feb 21 04:18 PM
RECUPERO ANTHONY J	President, Commercial Ops	Feb 18 '25	Sale	16.86	9,531	160,732	287,866	Feb 21 04:17 PM
DUNN JEFFREY W	Director	Feb 18 '25	Sale	16.77	1,619	27,152	15,191	Feb 21 04:16 PM
DUNN JEFFREY W	Director	Feb 03 '25	Sale	16.51	337	5,562	17,290	Feb 05 06:09 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jan 02 '25	Sale	13.90	3,670	51,014	222,814	Jan 06 06:58 PM
Maheshwari Anshul	Chief Financial Officer	Jan 02 '25	Sale	13.91	5,304	73,802	189,319	Jan 06 06:56 PM
DUNN JEFFREY W	Director	Nov 18 '24	Sale	12.43	1,609	20,001	20,431	Nov 20 05:13 PM
RECUPERO ANTHONY J	President, Commercial Ops	Nov 18 '24	Sale	12.60	3,937	49,609	228,554	Nov 20 05:12 PM
RECUPERO ANTHONY J	President, Commercial Ops	Nov 19 '24	Sale	12.17	2,070	25,195	226,484	Nov 20 05:12 PM
Maheshwari Anshul	Chief Financial Officer	Nov 18 '24	Sale	12.68	2,439	30,937	194,623	Nov 20 05:11 PM
FRANCIS LAURA	Chief Executive Officer	Nov 18 '24	Sale	12.58	10,048	126,354	482,875	Nov 20 05:10 PM
ANTHONY JOHN RECUPERO	Officer	Nov 19 '24	Proposed Sale	12.36	2,070	25,585		Nov 19 04:24 PM
DUNN JEFFREY W	Director	Nov 04 '24	Sale	13.55	341	4,621	22,040	Nov 06 06:19 PM
RECUPERO ANTHONY J	President, Commercial Ops	Oct 02 '24	Sale	13.58	3,305	44,877	233,412	Oct 04 06:55 PM
RECUPERO ANTHONY J	President, Commercial Ops	Oct 03 '24	Sale	13.60	921	12,526	232,491	Oct 04 06:55 PM
Maheshwari Anshul	Chief Financial Officer	Oct 02 '24	Sale	13.58	3,305	44,886	197,062	Oct 04 06:54 PM
ANTHONY JOHN RECUPERO	Officer	Oct 03 '24	Proposed Sale	13.60	921	12,526		Oct 03 04:28 PM
Maheshwari Anshul	Chief Financial Officer	Sep 03 '24	Sale	16.35	1,414	23,119	200,367	Sep 04 05:51 PM
ANSHUL MAHESHWARI	Officer	Sep 03 '24	Proposed Sale	16.62	1,414	23,501		Sep 03 04:21 PM
RECUPERO ANTHONY J	President, Commercial Ops	Aug 16 '24	Sale	13.84	3,905	54,037	238,804	Aug 20 07:54 PM
RECUPERO ANTHONY J	President, Commercial Ops	Aug 19 '24	Sale	14.17	2,087	29,569	236,717	Aug 20 07:54 PM
Maheshwari Anshul	Chief Financial Officer	Aug 16 '24	Sale	13.87	2,418	33,538	198,762	Aug 20 07:53 PM
FRANCIS LAURA	Chief Executive Officer	Aug 16 '24	Sale	13.84	9,967	137,970	492,923	Aug 20 07:52 PM
DUNN JEFFREY W	Director	Aug 16 '24	Sale	13.84	1,580	21,867	25,212	Aug 20 07:51 PM
ANTHONY JOHN RECUPERO	Officer	Aug 19 '24	Proposed Sale	13.87	2,087	28,947		Aug 19 04:27 PM
DUNN JEFFREY W	Director	Aug 02 '24	Sale	14.32	343	4,912	26,792	Aug 06 05:38 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jul 02 '24	Sale	12.92	3,309	42,755	243,629	Jul 05 05:48 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jul 03 '24	Sale	13.05	920	12,007	242,709	Jul 05 05:48 PM
Maheshwari Anshul	Chief Financial Officer	Jul 02 '24	Sale	12.90	3,309	42,694	201,180	Jul 05 05:41 PM
FRANCIS LAURA	Chief Executive Officer	Jun 14 '24	Option Exercise	4.38	68,669	300,710	512,753	Jun 17 08:20 PM
DUNN JEFFREY W	Director	Jun 10 '24	Sale	12.99	341	4,430	18,814	Jun 12 08:36 PM

NVCR

NovoCure Ltd

SIBN

SI-BONE Inc

Upgrade your FINVIZ experience